Smith Victoria M, Lomas Oliver, Constantine Donna, Palmer Lianne, Schuh Anna H, Bruce David, Gonchar Oksana, Macip Salvador, Jayne Sandrine, Dyer Martin J S, Eyre Toby A
Mechanisms of Cancer and Ageing Laboratory, Department of Molecular and Cell Biology, and.
The Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.
Blood Adv. 2020 Feb 11;4(3):525-529. doi: 10.1182/bloodadvances.2019000917.
Treatment of relapsed refractory T-PLL with venetoclax monotherapy results in only transient and minor clinical responses. In vitro analyses pre- and postvenetoclax indicate dual dependence on BCL2 and MCL1; combined BCL2 and MCL1 inhibition are synergistic.
用维奈克拉单药治疗复发难治性T细胞幼淋巴细胞白血病仅产生短暂和轻微的临床反应。维奈克拉治疗前后的体外分析表明对BCL2和MCL1存在双重依赖性；联合抑制BCL2和MCL1具有协同作用。
